LNTHLantheus Holdings, Inc.
Price
+99%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality strong, nothing alarming, price roughly fair, growth steady, the market undecided.
We are the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes. We classify our products into three product categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Our Radiopharmaceutical Oncology product helps healthcare professionals (“HCPs”) Find, Fight and Follow cancer.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Lantheus Holdings, Inc. (LNTH) reported revenue of $388M in Q2 2026 (quarter ended Jun 30, 2026), up 2.7% from the same quarter a year earlier. That came with a gross margin of 62% and net income of $75M (19% of revenue). For the full year FY2025, revenue was $1.54B (+0.5% year on year) and net income $234M. Its largest product in Q2 2026 was PYLARIFY at $240M, 55% of the disclosed total, well ahead of Cardiology at 20%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 2, 2026As previously disclosed, on August 3, 2026, Lantheus Holdings, Inc., a Delaware corporation (“Lantheus” or the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among the Company, Curium US Holdings LLC, a Delaware limited liability company (“Parent”), and Coco Merger Sub Inc., a …Other event · Form 8-K
- Sep 21, 2026As previously disclosed, on August 3, 2026, Lantheus Holdings, Inc., a Delaware corporation (“Lantheus” or the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among the Company, Curium US Holdings LLC, a Delaware limited liability company (“Parent”), and Coco Merger Sub Inc., a …Other event · Form 8-K
- Aug 6, 2026Lantheus Reports Second Quarter 2026 Financial Results.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $439.0MThe company’s own SEC segment disclosure.
- PYLARIFY$240.4M55%
- Cardiology$88.3M20%
- Neuraceq$39.6M9%
- Neurology$39.6M9%
- Strategic Partnerships And Other$19.9M5%
- License and Royalty$11.2M3%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, Specialty & Generic
Ranks #5 of 41 by RyuScore